{"id":"https://openalex.org/W4361235960","doi":"https://doi.org/10.1158/0008-5472.c.6509576.v1","title":"Data from Emergence of High-Avidity Melan-A\u2013Specific Clonotypes as a Reflection of Anti\u2013PD-1 Clinical Efficacy","display_name":"Data from Emergence of High-Avidity Melan-A\u2013Specific Clonotypes as a Reflection of Anti\u2013PD-1 Clinical Efficacy","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361235960","doi":"https://doi.org/10.1158/0008-5472.c.6509576.v1"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.c.6509576.v1","doi":"https://doi.org/10.1158/0008-5472.c.6509576.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6509576.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/0008-5472.c.6509576.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006738419","display_name":"Sylvain Simon","orcid":"https://orcid.org/0000-0001-5985-3946","observed_orcids":["https://orcid.org/0000-0001-5985-3946"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sylvain Simon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033376651","display_name":"Virginie Vignard","orcid":"https://orcid.org/0000-0002-6702-2824","observed_orcids":["https://orcid.org/0000-0002-6702-2824"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Virginie Vignard","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045260573","display_name":"\u00c9milie Varey","orcid":"https://orcid.org/0000-0002-3013-2472","observed_orcids":["https://orcid.org/0000-0002-3013-2472"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emilie Varey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016111785","display_name":"Tiphaine Parrot","orcid":"https://orcid.org/0000-0001-9625-6825","observed_orcids":["https://orcid.org/0000-0001-9625-6825"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tiphaine Parrot","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019547050","display_name":"Anne\u2010Chantal Knol","orcid":"https://orcid.org/0000-0003-4011-5008","observed_orcids":["https://orcid.org/0000-0003-4011-5008"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anne-Chantal Knol","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001247907","display_name":"Amir Khammari","orcid":"https://orcid.org/0000-0001-9328-8004","observed_orcids":["https://orcid.org/0000-0001-9328-8004"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amir Khammari","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031244376","display_name":"Nadine Gervois","orcid":"https://orcid.org/0000-0002-0092-3919","observed_orcids":["https://orcid.org/0000-0002-0092-3919"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nadine Gervois","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009482796","display_name":"Fran\u00e7ois Lang","orcid":"https://orcid.org/0000-0002-0762-4647","observed_orcids":["https://orcid.org/0000-0002-0762-4647"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Francois Lang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002644565","display_name":"Brigitte Dr\u00e9no","orcid":"https://orcid.org/0000-0001-5574-5825","observed_orcids":["https://orcid.org/0000-0001-5574-5825"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brigitte Dreno","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5044083912","display_name":"Nathalie Labarri\u00e8re","orcid":"https://orcid.org/0000-0002-1407-6546","observed_orcids":["https://orcid.org/0000-0002-1407-6546"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nathalie Labarriere","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8799999952316284},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8970000147819519},{"id":"https://openalex.org/keywords/melan-a","display_name":"Melan-A","score":0.8849999904632568},{"id":"https://openalex.org/keywords/tcr-repertoire","display_name":"T cell receptor repertoire","score":0.8149999976158142},{"id":"https://openalex.org/keywords/clonotype-expansion","display_name":"clonotype expansion","score":0.703000009059906},{"id":"https://openalex.org/keywords/t-cell-avidity","display_name":"T cell avidity","score":0.7310000061988831},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.9020000100135803},{"id":"https://openalex.org/keywords/tigit","display_name":"TIGIT","score":0.9929999709129333},{"id":"https://openalex.org/keywords/treatment-response-biomarkers","display_name":"treatment response biomarkers","score":0.7630000114440918},{"id":"https://openalex.org/keywords/neoantigen-specific-t-cells","display_name":"neoantigen-specific T cells","score":0.722000002861023},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C2779118045","wikidata":"https://www.wikidata.org/wiki/Q21114021","display_name":"TIGIT","level":4,"score":0.7326564788818359},{"id":"https://openalex.org/C179223381","wikidata":"https://www.wikidata.org/wiki/Q419425","display_name":"Avidity","level":3,"score":0.7134037017822266},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.58540278673172},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5453335046768188},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5253036618232727},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5134983658790588},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5030097365379333},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5007894039154053},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.42784231901168823},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.42278435826301575},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3199884295463562}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.c.6509576.v1","doi":"https://doi.org/10.1158/0008-5472.c.6509576.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6509576.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.c.6509576.v1","doi":"https://doi.org/10.1158/0008-5472.c.6509576.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6509576.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2769385333","https://openalex.org/W4361256967","https://openalex.org/W4361256859","https://openalex.org/W4361256849","https://openalex.org/W4361236003","https://openalex.org/W7042939042","https://openalex.org/W2257411819","https://openalex.org/W4400272191","https://openalex.org/W2778514225","https://openalex.org/W7165021883"],"abstract_inverted_index":{"Abstract":[0],"Therapeutic":[1],"strategies":[2],"using":[3],"anti\u2013PD-1\u2013blocking":[4],"antibodies":[5],"reported":[6],"unparalleled":[7],"effectiveness":[8],"for":[9,91],"melanoma":[10,43],"immunotherapy,":[11],"but":[12],"deciphering":[13],"immune":[14],"responses":[15],"modulated":[16],"by":[17,107],"anti\u2013PD-1":[18,101,129],"treatment":[19,51,145],"remains":[20],"a":[21,73,79,87,108,141],"crucial":[22],"issue.":[23],"Here,":[24],"we":[25],"analyzed":[26],"the":[27,32,38,120,134],"composition":[28],"and":[29,46,103,113],"functions":[30],"of":[31,41,50,57,111,122,136,144],"large":[33],"Melan-A\u2013specific":[34,58,138],"T-cell":[35],"repertoire":[36],"in":[37,69,76,117],"peripheral":[39],"blood":[40],"9":[42],"patients":[44,77],"before":[45,62],"after":[47],"2":[48],"months":[49],"with":[52,72,78],"anti\u2013PD-1.":[53],"We":[54],"observed":[55],"amplification":[56],"V\u00df":[59,67,84,96],"subfamilies":[60,85,97],"undetectable":[61],"therapy":[63,102],"(thereafter":[64],"called":[65],"emerging":[66,83],"subfamilies)":[68],"responding":[70],"patients,":[71],"predominant":[74],"expansion":[75],"complete":[80],"response.":[81],"These":[82],"displayed":[86],"higher":[88],"functional":[89],"avidity":[90],"their":[92],"cognate":[93],"antigen":[94],"than":[95],"not":[98],"amplified":[99],"upon":[100,128],"could":[104],"be":[105],"identified":[106],"sustained":[109],"coexpression":[110],"PD-1":[112],"TIGIT":[114],"receptors.":[115],"Thus,":[116],"addition":[118],"to":[119],"emergence":[121,135],"neoantigen-specific":[123],"T":[124],"cells":[125],"previously":[126],"documented":[127],"therapy,":[130],"our":[131],"work":[132],"describes":[133],"high-avidity":[137],"clonotypes":[139],"as":[140],"surrogate":[142],"marker":[143],"efficacy.":[146],"Cancer":[147],"Res;":[148],"77(24);":[149],"7083\u201393.":[150],"\u00a92017":[151],"AACR.":[152]},"counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2023-03-31T00:00:00"}